Endocyte (ECYT) Stock Research, Analysis & News

Quick Analysis on Endocyte (ECYT) Stock as of December 12, 2017

The Stock pays no dividend
Average trading volume is relatively low at 0
(See more information about Endocyte (ECYT) Stock below)

Endocyte (ECYT) Stock Profile Summary

Endocyte, Inc., a biopharmaceutical company, engages in developing targeted therapies for the treatment of cancer and inflammatory diseases. The company uses its proprietary technology to create novel small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized targeted therapies. Its SMDCs target receptors that are over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently, and over longer periods of time than would be possible with the untargeted drug alone. The companys principal SMDC product, EC145, has been evaluated in a randomized phase 2 clinical trial for the treatment of women with platinum-resistant ovarian cancer, and it also completed a phase 2 single-arm clinical trial for advanced non-small cell lung cancer. Its companion imaging diagnostics are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. Endocyte, Inc. was founded in 1995 and is based in West Lafayette, Indiana.

Endocyte (ECYT) Stock Key Statistics Research and Analysis as of December 12, 2017

Stock Research on Endocyte (ECYT)

Latest Market News on Endocyte (ECYT)


Click here to find the latest news on Endocyte (ECYT)

Looking for Market Opportunties?


Today's Most Active Stocks
Today's Biggest Price % Gainers
Today's Biggest Price % Losers
Today's Unusual Rising Volume Stocks
Today's Unusual Falling Volume Stocks
Research Reports
Earning Calendar
ETF Center